Taysha Gene Therapies

TSHA

Valor de mercado US$ 1,18 bi

DALLAS, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on October 1, 2026, the Compensation Committee of Taysha's Board of Directors granted four new employees restricted stock units (RSUs) representing 384,000 shares of the Company's common stock and an option to purchase 92,400 shares of the Company's common stock in connection with their employment. The RSUs and stock option were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).

DALLAS, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced multiple encore presentations supporting its TSHA-102 program in clinical evaluation for Rett syndrome at the 55th Child Neurology Society Annual Meeting, taking place in Montréal, Québec, Canada, from October 14 – 17, 2026. The presentations will highlight data previously shared at the 2026 International Rett Syndrome Foundation (IRSF) Scientific Meeting.

Taysha Gene Therapies offers a speculative opportunity, hinging on durable clinical gains, safety, and disciplined execution for TSHA-102 in Rett syndrome. TSHA's $455.4M cash runway extends into H2 2028, supporting pivotal data collection and manufacturing scale-up without immediate dependence on accelerated regulatory filing. TSHA-102's early data show deepening, durable functional gains in Rett patients, but pivotal efficacy, safety, and manufacturing qualification remain key investment inflection points.

With industrials, energy, and tech stocks undergirding an S&P 500 that is hovering near all-time highs, investors looking for high-upside companies may be resigned to more speculative plays. While it's true that some long-established firms have posted surprising rallies in recent trading sessions, a combination of consumer reticence and stretched valuations means that many go-to investments may not see much near-term growth.

DALLAS, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on September 1, 2026, the Compensation Committee of Taysha's Board of Directors granted five new employees restricted stock units (RSUs) representing 314,000 shares of the Company's common stock and an option to purchase 92,400 shares of the Company's common stock in connection with their employment. The RSUs and stock option were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).

Taysha Gene Therapies, Inc. (TSHA) Q2 2026 Earnings Call Transcript

Taysha Gene Therapies NASDAQ: TSHA said it completed dosing in its REVEAL pivotal trial and ASPIRE trial for TSHA-102, its gene therapy candidate for Rett syndrome, while preparing for a potential biologics license application submission.

Completed dosing in the REVEAL pivotal (N=17) and ASPIRE (N=4) trials evaluating TSHA-102 for Rett syndrome; expect to report topline data from 6 ‑ month interim analysis and FDA feedback on the BLA submission pathway in 1H 2027

DALLAS, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on August 3, 2026, the Compensation Committee of Taysha's Board of Directors granted one new employee restricted stock units (RSUs) representing 144,000 shares of the Company's common stock and an option to purchase 92,400 shares of the Company's common stock in connection with their employment. The RSUs and stock option were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).

DALLAS, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the second quarter ended June 30, 2026, and host a corporate update conference call and webcast on Tuesday, August 11, 2026, at 4:30 PM Eastern Time.